ap-pa02
Biologicalexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04596319)
Timeline
Indications
Mechanism of action
- BacteriophageOTHER
Bacteriophage other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05616221 | Phase 2 | Jan 31, 2023 | Armata Pharmaceuticals, Inc. |
| NCT04596319 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Armata Pharmaceuticals, Inc., Cystic Fibrosis Foundation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Armata Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2020 |
| Cystic Fibrosis Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1